Inclusion Criteria:

- Age≥18 years, ≤70 years, male or female;

- Advanced collecting duct carcinoma of the kidney is diagnosed histologically or
pathologically ;

- Have not received anti-angiogenesis targeted drug therapy and systemic chemotherapy;

- Have at least one measurable tumor lesion (Response Evaluation Criteria In Solid
Tumors);

- Eastern Cooperative Oncology Group（ECOG) performance scale is 0 or 1;

- The expected life span is ≥12 weeks;

- No contraindications for chemotherapy, with enough liver function and renal function
and normal ECG recording.Peripheral hemogram: neutrophil≥1.5×109/L, Plt≥100×109/L,
Hgb≥90 g/L;Renal function: serum creatinine≤1.5 folds the upper limit of normal
(ULN); For patients with non-metastatic liver dysfunction: alanine aminotransferase
and aspartate aminotransferase≤2.5 ULN, For patients with metastatic liver
dysfunction: alanine aminotransferase and aspartate aminotransferase≤5 ULN;

- The patients participate voluntarily and have signed the informed consent form.

Exclusion Criteria:

- Pregnant and lactating women, or female patients of child-bearing age without taking
contraceptive measures;

- Patients with severe acute infection without being controlled effectively or having
pyogenic and chronic infections with persistently unhealed wounds;

- Past history of serious heart diseases, including: cardiac function classification
≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring
anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled
hypertension;

- Patients with a history of HIV infection or active phase of chronic hepatitis B/C;

- negative imaging examination result 4 weeks prior to enrollment);

- Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs);

- A history of allogeneic organ transplantation;

- Patients with evidence of hemorrhagic constitution or a past history of hemorrhage;

- Patients currently receiving renal dialysis;

- Past or present concomitant tumors with the primary lesions or histological
characteristics different from the tumors evaluated in this study, excluding other
tumor cured longer than 3 years before enrollment;

- Patients participating in other clinical trials simultaneously;

- Other conditions unsatisfying the inclusion criteria in the investigator's opinions.